BOLANLE OLAYIWOLE: Open Payments
NPI 1780187138 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,285 in 45 payments from 8 companies in 2025. Trend: 2023 $1,886 · 2024 $1,282 · 2025 $2,285
Food & beverage: $2,176Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 22 | $818 |
| Neurocrine BioSciences, Inc. | 10 | $340 |
| Janssen Scientific Affairs, LLC | 2 | $286 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $262 |
| Janssen Pharmaceuticals, Inc | 2 | $236 |
| Luye Pharma (USA) Ltd. | 2 | $152 |
| Otsuka America Pharmaceutical, Inc. | 3 | $140 |
| Alkermes, Inc. | 2 | $52 |
Products named: AUSTEDO XR, INVEGA SUSTENNA, INGREZZA, CAPLYTA, ERZOFRI EXTENDED-RELEASE, ABILIFY ASIMTUFII, UZEDY, ARISTADA.
Industry payments across TX — which companies pay providers there.
